Search Results - Collaboration+Sought+%3e+Materials+Available

68 Results

Sort By:

Anti-Nucleoprotein Crimean-Congo Hemorrhagic Fever Virus Monoclonal Antibodies for Assay Creation

Crimean-Congo hemorrhagic fever (CCHF) is the most widespread form of viral hemorrhagic fever, found in Eastern and Southern Europe, the Mediterranean, northwestern China, central Asia, Africa, the Middle East, and the Indian subcontinent. Typically beginning with non-specific fever, myalgia, nausea, diarrhea, and general malaise, symptoms of infection...

Published: 7/3/2025 | Inventor(s): Daniel Douek, David Hawman, Leonid Serebryannyy, Noemia Santana Lima, Chaim Schramm, Sarah Smith (Kerscher), Amy Henry, Alicen Spaulding

Keywords(s):

Category(s): Application, Application > Diagnostics, Collaboration Sought, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Antibodies, TherapeuticArea, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, TherapeuticArea > Rare/Neglected Diseases

EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques

Enterovirus D68 (EV-D68) has been linked to the widespread outbreaks of respiratory illness and acute flaccid myelitis (AFM) in the United States and Europe in 2014, 2016, and 2018. Although EV-D68 is now the most frequently encountered enterovirus (41.1% of cases), with an estimated global prevalence of 4%, there are no specific, FDA-approved therapeutic...

Published: 7/2/2025 | Inventor(s): Tracy Ruckwardt, Daniel Moss, Peter Krug, Masaru Kanekiyo

Keywords(s):

Category(s): Application, Application > Diagnostics, Application > Therapeutics, Application > Vaccines, Collaboration Sought, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts, ResearchProducts > Antibodies, TherapeuticArea, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease

Discovery of potent and selective D3 antagonist with alleviated hERG liability and optimized pharmacokinetic properties

One of the most challenging hurdles in creating safe and effective new medicines for many diseases is finding drugs that are effective without causing off-target cardiac issues, such as cardiac arrythmias. In collaboration with NIDA, scientists at NCATS have developed a series of novel and highly specific dopamine D3 receptor agonists and antagonists...

Published: 6/13/2025 | Inventor(s): Khalida Shamim, Wenwei Huang, Wei Zheng, Catherine Chen, Xiuli Huang, Xin Hu, Xin Xu, Pranav Shah, Elias Padilha, Philip Sanderson, Amy Newman

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, TherapeuticArea > Neurology, TherapeuticArea > Psychiatry/Mental Health

Antibodies to TMC1 Protein for Hearing Loss

This technology includes antibodies for TMC1 protein as a treatment for hearing loss. TMC1 is one of the common genes causing hereditary hearing loss. Our laboratory used synthetic peptides corresponding to the TMC1 protein to immunize rabbits. The resulting antisera were shown to bind to TMC1 protein expressed in heterologous expression systems. TMC1...

Published: 5/19/2025 | Inventor(s): Andrew Griffith, Tomoko Makishima, Valentina Labay

Keywords(s):

Category(s): Application > Research Materials, Application > Therapeutics, ResearchProducts > Antibodies, Collaboration Sought > Licensing, Collaboration Sought > Materials Available

Blocking CD38 using Daratumumab F(ab)2 to Protect Natural Killer Cells from Daratumumab-induced Apoptosis and Cell Death for the Treatment of Multiple Myeloma

This technology includes the method of blocking CD38 in expanded natural killer (NK) cell therapy in combination with daratumumab in patients with multiple myeloma. Our in vitro studies have already confirmed the addition of NK cells to myeloma cells that have been exposed to daratumumab enhances myeloma killing compared to single agent treatment. Studies...

Published: 8/12/2024 | Inventor(s): Richard Childs, Jorge Luis Espinoza-Calderon, Maria Berg

Keywords(s):

Category(s): Application > Research Materials, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Human Cell Lines, TherapeuticArea > Oncology

Monoclonal Antibody Against Human Zinc Finger RNA-binding Protein (ZFR)

This technology includes monoclonal antibody was raised in mice against amino acids 703-1074 of ZFR. Antibody specificity was confirmed by immunoblotting lysates from cells depleted of ZFR using shRNAs.

Published: 6/9/2025 | Inventor(s): John Hogg, Nazmul Haque

Keywords(s):

Category(s): Application > Research Materials, Collaboration Sought > Materials Available, ResearchProducts > Antibodies

Antibody to Mitochondrial Uniporter (MCU

This technology includes a generated polyclonal antibody in rabbit that detects the mitochondrial uniporter (MCU) protein. This antibody was created by immunizing rabbits with a synthesized sequence of the MCU protein and can be used to identify and quantify MCU protein in various tissues. The polyclonal nature of the antibody ensures it recognizes...

Published: 5/15/2025 | Inventor(s): Toren Finkel, Xin Pan

Keywords(s):

Category(s): Application > Research Materials, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Antibodies

Human Monoclonal Antibodies to Generate Chimeric Antigen Receptor (CAR) T-cells to Treat Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC).

This technology includes six human monoclonal antibodies (mAbs) that target tumor antigens derived from the CT-RCC HERV-E (human endogenous retrovirus type E) to generate Chimeric Antigen Receptor (CAR) T cells to treat patients with advanced clear cell renal cell carcinoma (ccRCC). These mAbs were identified from Adagene Inc’s human antibody...

Published: 5/14/2025 | Inventor(s): Richard Childs, Long Chen, Elena Cherkasova

Keywords(s):

Category(s): Application > Diagnostics, Application > Research Materials, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Antibodies, TherapeuticArea > Oncology

ApoE-ApoCII Chimeric Peptides for Treating Hypertriglyceridemia

This technology includes apoE-apoCII chimeric peptides that possess the ability to lower the triglyceride level both in vitro and in vivo. These peptides can be used for treating hypertriglyceridemia and alleviating other diseases and conditions associated with increased triglycerides.

Published: 9/11/2024 | Inventor(s): Soumitra Ghosh, Chih-Hung (Larry) Lo, Alan Remaley, Denis Sviridov, Anna Wolska, Madhav (Matt) Devalaraja

Keywords(s):

Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, TherapeuticArea > Cardiology

Generation of Safe-harbor Gene Targeting Donor Plasmids

This technology includes two safe harbor gene targeting donors, specifically designed for applications in the study of induced pluripotent stem cells (iPSC). These include the pAAVS1D-CMV.RFP-EF1a.copGFPpuro and pAAVS1-iCLHN donors. A key feature of these donors is their ability to integrate various transgenes into specific loci through homologous recombination,...

Published: 4/9/2025 | Inventor(s): Jizhong Zou, Mahendra Rao

Keywords(s):

Category(s): Application > Research Materials, Collaboration Sought > Materials Available, ResearchProducts > Human iPSC Lines, ResearchProducts > Plasmids/Vectors

1 2 3 4 5 6 7